A Randomized, Double-blinded, Partial-open, Placebo/Active-controlled, Single/Multiple Dosing, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of IY-828026 in Healthy Adult Volunteers
Latest Information Update: 01 Apr 2026
At a glance
- Drugs IY 828026 (Primary)
- Indications Gastrointestinal disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Il-Yang Pharmaceutical
Most Recent Events
- 27 Mar 2026 Status changed from not yet recruiting to recruiting.
- 17 Mar 2026 New trial record